• Radiation Therapy
      • Treatment Delivery
        • Elekta Unity Elekta Unity
        • Versa HD Versa HD
        • Elekta Harmony Elekta Harmony
        • Elekta Infinity Elekta Infinity
        • Elekta Synergy Elekta Synergy
      • Treatment Management
        • Monaco
        • ProKnow
      • Quality Assurance
        • Machine QA
        • Patient QA
    • Stereotactic Radiosurgery
      • Delivery
        • Elekta Esprit Elekta Esprit
        • Leksell Gamma Knife Icon Leksell Gamma Knife Icon
        • Leksell Gamma Knife Perfexion Leksell Gamma Knife Perfexion
        • Versa HD Versa HD
      • Treatment Planning
        • Leksell Gamma Knife Lightning
        • Leksell GammaPlan
    • Oncology Informatics
      • MOSAIQ Plaza
        • Subscribe to Better
        • Professional Services
        • Interoperability
      • Elekta Axis Cloud
    • Brachytherapy
      • Delivery
        • Elekta Studio Elekta Studio
        • ImagingRing ImagingRing
        • Oncentra Brachy Oncentra Brachy
        • Venezia Venezia
        • Flexitron Flexitron
        • Geneva Geneva
      • Body Sites
        • Head and Neck
        • Bronchus and Oesophagus
        • Breast
        • Skin
        • Prostate
        • Rectum
        • Bladder
        • Gynecology
    • Neurosurgery
      • Delivery
        • Leksell Vantage Stereotactic System Leksell Vantage Stereotactic System
        • Leksell Stereotactic System Leksell Stereotactic System
    • Veterinary Radiation Therapy
    • Elekta Care Customer Services
    • Elekta Care 360
    • Elekta Care Learning
    • Elekta Care Community
    • Elekta Partner Community
    • MR-Linac Treatment
    • Brachytherapy Treatment
    • Gamma Knife Treatment
    • Radiation Therapy Treatment
    • Treatment Centers
    • Company
    • Partnering with Elekta
    • About us
      • About us
        • Board of Directors
        • Code of Conduct
        • Corporate Citizenship
        • Executive Management
        • Integrity Line
        • Programs
        • Sponsorship and Donation
        • Story
    • Sustainability
    • Corporate Governance
      • Corporate Governance
        • Shareholders’ meetings
          • Board of Directors
            • Executive Management
              • Auditors
              • Reports
          • Investors
            • Investors
              • Investment case
                • Outlook
                • The share
                  • Financials
                    • Funding
                      • Reports & presentations
                      • Press releases
                      • IR calendar
                      • IR contacts
                  • Newsroom
                    • Newsroom
                      • Press Releases
                      • FOCUS Magazine
                      • Events
                      • Image bank
                  • Careers at Elekta
                    • Jobs
                  • Reimbursement Support & Policy
                ENSV
                Login
                • Products
                  • Radiation Therapy
                    • Treatment Delivery
                      • Elekta Unity
                      • Versa HD
                      • Elekta Harmony
                      • Elekta Infinity
                      • Elekta Synergy
                    • Treatment Management
                      • Monaco
                      • ProKnow
                    • Quality Assurance
                      • Machine QA
                      • Patient QA
                  • Stereotactic Radiosurgery
                    • Delivery
                      • Elekta Esprit
                      • Leksell Gamma Knife Icon
                      • Leksell Gamma Knife Perfexion
                    • Treatment Planning
                      • Leksell Gamma Knife Lightning
                      • Leksell GammaPlan
                    • Versa HD
                  • Oncology Informatics
                    • MOSAIQ Plaza
                      • Subscribe to Better
                      • Professional Services
                      • Interoperability
                    • Elekta Axis Cloud
                  • Brachytherapy
                    • Elekta Studio
                    • ImagingRing
                    • Venezia
                    • Flexitron
                    • Geneva
                    • Head and Neck
                    • Bronchus and Oesophagus
                    • Breast
                    • Skin
                    • Prostate
                    • Rectum
                    • Bladder
                    • Gynecology
                    • Oncentra Brachy
                  • Neurosurgery
                    • Leksell Vantage Stereotactic System
                    • Leksell Stereotactic System
                  • Veterinary Radiation Therapy
                • Services
                  • Elekta Care Customer Services
                  • Elekta Care 360
                  • Elekta Care Learning
                  • Elekta Care Community
                  • Elekta Partner Community
                • Patients
                  • MR-Linac Treatment
                  • Brachytherapy Treatment
                  • Gamma Knife Treatment
                  • Radiation Therapy Treatment
                  • Treatment Centers
                • Company
                  • Partnering with Elekta
                  • About us
                    • Board of Directors
                    • Code of Conduct
                    • Corporate Citizenship
                    • Executive Management
                    • Integrity Line
                    • Programs
                    • Sponsorship and Donation
                    • Story
                  • Sustainability
                  • Corporate Governance
                    • Shareholders’ meetings
                      • Board of Directors
                        • Executive Management
                          • Auditors
                          • Reports
                        • Investors
                          • Investment case
                            • Outlook
                            • The share
                              • Financials
                                • Funding
                                  • Reports & presentations
                                  • Press releases
                                  • IR calendar
                                  • IR contacts
                                • Newsroom
                                  • Press Releases
                                  • FOCUS Magazine
                                  • Events
                                  • Image bank
                                • Careers at Elekta
                                  • Jobs
                                • Reimbursement Support & Policy
                              • Contact
                              • Medical Affairs
                              • Regulatory Affairs
                              • Suppliers
                                • About Elekta Procurement
                                • Sustainable Sourcing
                                • Performance Management
                                  • Production Part Approval Process
                                  • Supplier Escalation Form
                                  • Non Conformance Management
                                  • Supplier Performance Management
                                  • Obsolescence Management
                                • Compliance Management
                                • Invoicing Process
                                • Elekta T&C
                                • Documents & Training
                                • Our Global Presence
                              • Facebook
                              • LinkedIn
                              • Twitter
                              • Instagram
                              • Youtube

                              Interim report May – July 2014/15

                              August 28, 2014
                              • Order bookings increased 12* percent to SEK 2,341 M (2,027).
                              • Net sales decreased 4* percent to SEK 1,865 M (1,912).
                              • EBITA amounted to SEK -38 M (148) before non-recurring items. Currency effects were neutral.
                              • Net income amounted to SEK -137 M (-8). Earnings per share amounted to SEK -0.36 (-0.01) before dilution and SEK -0.36 (-0.01) after dilution.
                              • Cash flow after continuous investments amounted to SEK -670 M (-584). Cash conversion is targeted to return to around 70 percent for the fiscal year.

                              Outlook

                              • There are strong drivers for growth in radiation therapy. Elekta’s ambition is to continue to grow faster than the market. The financial objective is an annual net sales growth exceeding 10 percent in local currency.
                              • Due to temporary lower growth and higher execution risks in some emerging markets and a focus on tighter management of working capital, net sales is expected to grow by 7-9 percent in local currency for the fiscal year 2014/15. Currently 2014/15 is expected to finish in the lower range of the interval.
                              • EBITA is expected to grow by approximately 10 percent (changed from “10 percent or more”) in local currency for the fiscal year 2014/15, compared with last year. Exchange rate movements are expected to have a neutral impact on EBITA growth in SEK.

                              President and CEO comments
                              During the first quarter of the fiscal year 2014/15 we continued to see mixed development in our markets. We are pleased that order momentum recovered and order bookings grew by 12* percent compared to the first quarter last year. Net sales and cash flow were weak. Based on current market conditions and our order backlog we reiterate our net sales guidance for the year with a growth of 7-9 percent in local currency, but we currently expect the result to be in the lower range of the interval. EBITA is expected to grow approximately 10 percent.

                              Mixed market environment
                              We estimate that demand in the first quarter grew by low single-digits over the previous year. In the first quarter we saw a mixed market environment across our geographic areas. There was slower than expected growth in mature markets, especially in the US. In Asia, and other emerging markets, the market development was mixed in the first quarter but we are expecting a return to growth for the full year.  Due to macroeconomic and geopolitical circumstances there are increased risks in the full year plan. We remain cautiously optimistic, but are monitoring the situation closely.

                              Strong order bookings
                              Elekta’s order bookings increased by 12* percent in the first quarter, reflecting good demand for Elekta’s leading portfolio of cancer care solutions. Performance was good in Europe and North America. In Asia, the trend was mixed. India showed good growth. In Japan, orders were unchanged while the market and orders in China were seasonally lower than last year but full-year prospects are good.

                              After the relatively weak order intake last year, our global order volumes for Leksell Gamma Knife® continue to improve according to plan.

                              Weak delivery volumes
                              The first quarter is normally Elekta’s weakest. Net sales decreased by 4* percent. Deliveries in region EMEA were strong and we noticed a slight increase in Asia. North America had a weak quarter mainly due to delays in planned software installations. Software revenues are expected to recover during this fiscal year. Gross margin decreased to 34 percent (42). The decline is due to low software revenues and unfavorable project mix effects in the first quarter. EBITA before non-recurring items amounted to SEK -38 M (148). The lower result is an effect of the lower gross profit combined with cost increases according to plan.

                              Cash flow
                              Cash flow after continuous investments for the first quarter amounted to SEK -670 M (-584). Cash flow was impacted by the result from operations and inventory build-up for scheduled deliveries for the quarter and the remainder of the year. Compared with the fourth quarter, accounts receivable declined according to plan. Actions are in place to gradually improve cash flow during the year, with the ambition to return to a cash generation of around 70 percent for the year.

                              Supporting future growth
                              In the fourth quarter, and in line with the strategic agenda, we announced measures to enhance the efficiency of the organization to support continued growth. The activities in the program have, to a large extent, been executed and the related cash outflow amounted to SEK 33 M in the first quarter. The total program amounted to SEK 100 M. We have completed efficiency measures leading to staff reductions in our North American and Asian regional organizations. In addition, we announced our intent to close our office in Freiburg, Germany, and transfer the functions to Crawley, UK.

                              Continued progress in product development
                              We are in a high-investment phase within research and development. Our MRI-guided radiation therapy project is our largest research and development project to date. Recently, the Christie Hospital in the UK joined our research consortium for MRI-guided radiation therapy and Uppsala University Hospital has announced that it will be conducting research with MRI-guided radiation therapy via a bilateral research agreement with Elekta.

                              Outlook
                              The long-term underlying market growth remains strong. However, for this fiscal year, we see continued mixed development in our markets including higher execution risks in certain emerging markets. We reiterate our outlook for the full fiscal year of a net sales growth of 7-9 percent, in local currency, where we currently see 2014/15 finishing in the lower range of the interval.

                              EBITA is expected to increase approximately 10 percent in local currency compared with last year. Exchange rate movements are expected to have a neutral impact on EBITA growth in SEK.

                              Niklas Savander - President and CEO

                              * Compared with last fiscal year, based on unchanged exchange rates.

                              Conference call
                              Elekta will host a telephone conference at 13:45 – 14:30 CET on August 28, with President and CEO Niklas Savander and CFO Håkan Bergström.

                              To take part in the conference call, please dial in about 5-10 minutes in advance.

                              Swedish dial-in number: +46 (0)8 519 993 50, UK dial-in number: +44 (0)20 319 405 47, US dial-in number: +1 877 788 90 23.

                              The telephone conference will also be broadcasted over the internet (listen only). Please use the link:
                              http://event.onlineseminarsolutions.com/r.htm?e=835942&s=1&k=EAA8B50F1C78794463BD4A565734355A

                              Financial information
                              Interim report May – October 2014/15                        
                              November 27, 2014

                              Interim report May – January 2014/15                        
                              March 4, 2015

                              Year-end report May – April 2014/15                          
                              June 2, 2015

                              For further information, please contact:
                              Håkan Bergström, CFO, Elekta AB (publ)
                              +46 8 587 25 547, hakan.bergstrom@elekta.com

                              Johan Andersson, Director Investor Relations, Elekta AB (publ)
                              +46 702 100 451, johan.andersson@elekta.com

                              Elekta AB (publ)
                              Corporate registration number 556170-4015
                              Kungstensgatan 18, ­Box 7593, SE 103 93 Stockholm, Sweden

                              The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 13:00 CET on August 28, 2014.

                              Downloads

                              • The full report
                              • Products
                                • Radiation Therapy
                                • Stereotactic Radiosurgery
                                • Oncology Informatics
                                • Brachytherapy
                                • Neurosurgery
                                • Veterinary Radiation Therapy
                              • Services
                                • Elekta Care Customer Services
                                • Elekta Care 360
                                • Elekta Care Learning
                                • Elekta Care Community
                                • Elekta Partner Community
                              • Patients
                                • MR-Linac Treatment
                                • Brachytherapy Treatment
                                • Gamma Knife Treatment
                                • Radiation Therapy Treatment
                                • Treatment Centers
                              • Company
                                • Partnering with Elekta
                                • About us
                                • Sustainability
                                • Corporate Governance
                                • Investors
                                • Newsroom
                                • Careers at Elekta
                                • Country and regional pages
                                • Digital Product Security
                                • Offices
                              • Facebook
                              • LinkedIn
                              • Twitter
                              • Instagram
                              • Youtube
                              • ©2023 Elekta
                              • Legal notices
                              • Privacy policy
                              • Cookies
                              • Subscription center

                              Important Safety Information: Radiation therapy is not appropriate for all patients. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Refer to individual product labeling (instructions for use) for more complete information on product safety and effectiveness for its intended use.

                              Contact and Support

                              Offices Customer support
                              Please note: due to bot protection, submitting a non-work email may result in longer reponse times.

                              By clicking the 'Submit' button below you agree to the Elekta Privacy Policy.

                              © 2023 Elekta

                              • Legal notices
                              • Privacy policy
                              • Cookies
                              • Subscription center

                              Important Safety Information: Radiation therapy is not appropriate for all patients. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Refer to individual product labeling (instructions for use) for more complete information on product safety and effectiveness for its intended use.